E. Montefiore

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma

P. Marchetti, G. Cappellini, E. Proietti, 2015, Journal of Translational Medicine.

A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

R. Foà, A. Guarini, M. Napolitano, 2015, Blood transfusion = Trasfusione del sangue.

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

T. Di Pucchio, P. Marchetti, E. Bonmassar, 2006, Cancer research.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial

S. Hohaus, A. Tafuri, D. Prosperi, 2019, Clinical Cancer Research.

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

L. Castiello, D. Carlei, E. Aricò, 2022, Cancers.

Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals.

P. Borrow, C. Castilletti, M. Capobianchi, 2008, Vaccine.

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma

P. Marchetti, G. Cappellini, E. Proietti, 2015, Journal of Translational Medicine.